Director/PDMR Shareholding

RNS Number : 0273L
GlaxoSmithKline PLC
07 September 2021
 

GlaxoSmithKline plc   (the ' Company ')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

b)

Nature of the transaction

Following the vesting on 4 September 2021 of 25% of an award made on 14 February 2018 under the GlaxoSmithKline Deferred Investment Award Programme, Mr Miels will receive a cash payment of £409,730.64 less applicable tax withholding in respect of 27,706.968 notional Ordinary Shares.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£14.788

27,706.968

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2021-09-04

f)

Place of the transaction

 

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEDLFBFKLEBBB

Companies

GSK (GSK)
UK 100

Latest directors dealings